Kidney Transplant Rejection Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Kidney Transplant Rejection Overview

Kidney Transplant Rejection, is an allogeneic immunological response that leads to graft damage and graft function degradation. It frequently occurs in patients with insufficient immunosuppression or who do not take their medication as prescribed.

“Kidney Transplant Rejection Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Kidney Transplant Rejection Market.

The Kidney Transplant Rejection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Kidney Transplant Rejection Pipeline Report:

• Companies across the globe are diligently working toward developing novel Kidney Transplant Rejection treatment therapies with a considerable amount of success over the years. Kidney Transplant Rejection Key players such as – Sangamo Therapeutics, Horizon Therapeutics Plc/ Viela Bio, Medeor Therapeutics, Inc., CSL Behring, and others, are developing therapies for the Kidney Transplant Rejection treatment 
• Kidney Transplant Rejection Emerging therapies such as – TX200, Dazodalibep (HZN-4920), MDR-101, Clazakizumab, and others are expected to have a significant impact on the Kidney Transplant Rejection market in the coming years.   
• MDR-101, a cellular therapy manufactured from a living kidney donor’s blood and bone marrow cells. The therapy is intended to allow kidney transplant recipients who have a genetically or HLA-matched living kidney donor to cease taking all immunosuppressive (anti-rejection) drugs while maintaining long-term transplant kidney function and survival.

Route of Administration

Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Kidney Transplant Rejection Pipeline Therapeutics Assessment

• Kidney Transplant Rejection Assessment by Product Type
• Kidney Transplant Rejection By Stage and Product Type
• Kidney Transplant Rejection Assessment by Route of Administration
• Kidney Transplant Rejection By Stage and Route of Administration
• Kidney Transplant Rejection Assessment by Molecule Type
• Kidney Transplant Rejection by Stage and Molecule Type

DelveInsight’s Kidney Transplant Rejection Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Kidney Transplant Rejection Therapeutics Market include:

Key Companies developing therapies for the Kidney Transplant Rejection treatment are – Alphamab Oncology, AltruBio Inc., Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc., Bristol-Myers Squibb Co., Cynata Therapeutics Ltd., Eledon Pharmaceuticals Inc., Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte B, and others

Emerging Kidney Transplant Rejection Drugs Under Different Phases of Clinical Development Include:

• TX200: Sangamo Therapeutics
• Dazodalibep (HZN-4920): Horizon Therapeutics Plc/ Viela Bio
• MDR-101: Medeor Therapeutics, Inc.
• Clazakizumab: CSL Behring

Get a Free Sample PDF Report to know more about Kidney Transplant Rejection Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight

Kidney Transplant Rejection Pipeline Analysis:

The Kidney Transplant Rejection pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Kidney Transplant Rejection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Kidney Transplant Rejection Treatment.
• Kidney Transplant Rejection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Kidney Transplant Rejection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Kidney Transplant Rejection market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Kidney Transplant Rejection product details are provided in the report. Download the Kidney Transplant Rejection pipeline report to learn more about the emerging Kidney Transplant Rejection therapies

Scope of Kidney Transplant Rejection Pipeline Drug Insight    

• Coverage: Global
• Key Kidney Transplant Rejection Companies: Sangamo Therapeutics, Horizon Therapeutics Plc/ Viela Bio, Medeor Therapeutics, Inc., CSL Behring, and others
• Key Kidney Transplant Rejection Therapies: TX200, Dazodalibep (HZN-4920), MDR-101, Clazakizumab, and others
• Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies
• Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers 

Request for Sample PDF Report for Kidney Transplant Rejection Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Kidney Transplant Rejection drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com